Literature DB >> 10858395

Inhaled corticosteroids in stable COPD patients: do they have effects on cells and molecular mediators of airway inflammation?

B Balbi1, M Majori, S Bertacco, G Convertino, A Cuomo, C F Donner, A Pesci.   

Abstract

STUDY
OBJECTIVE: To investigate possible changes in cells and molecular mediators of airway inflammation following inhaled steroid treatment of stable COPD patients.
DESIGN: Six-week open preliminary prospective study.
SETTING: A university respiratory disease clinic. PATIENTS: : Stable COPD patients with mild disease. INTERVENTION: Six-week treatment with inhaled beclomethasone (1.5 mg die). MEASUREMENTS: The levels of interleukin (IL)-8, myeloperoxidase, eosinophilic cationic protein and tryptase, and cell numbers in bronchial lavage specimens were determined, and the symptom score, the endoscopic bronchitis index, and functional parameters were recorded.
RESULTS: After treatment there were significant reductions in the lavage levels of IL-8 ([mean +/- SEM] 1,603.4 +/- 331.2 vs 1,119.2 +/- 265.3 pg/mL, respectively; p = 0. 01) and myeloperoxidase (1,614.5 +/- 682.3 vs 511.2 +/- 144.2 microg/L, respectively; p = 0.05), in cell numbers (250.6 +/- 27.7 vs 186.3 +/- 11.5 cells x 10(3)/mL, respectively; p = 0.04), neutrophil proportion (59.7 +/- 14.3% vs 31.5 +/- 10.1%; p = 0.01), symptom score (4.5 +/- 0.6 vs 1.4 +/- 0.5; p = 0.01), and bronchitis index (8.5 +/- 0.8 vs 5.5 +/- 0.7; p = 0.007).
CONCLUSIONS: In stable patients with COPD, inhaled steroid treatment may induce changes on some cellular and molecular parameters of airway inflammation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10858395     DOI: 10.1378/chest.117.6.1633

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  9 in total

Review 1.  Benefits and risks of inhaled corticosteroids in chronic obstructive pulmonary disease.

Authors:  Marcel Bonay; Catherine Bancal; Bruno Crestani
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 2.  Tackling COPD: a multicomponent disease driven by inflammation.

Authors:  Peter Kardos; Joseph Keenan
Journal:  MedGenMed       Date:  2006-08-31

3.  Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease: How Significant is the Risk of Pneumonia and Should It Impact Use of Inhaled Corticosteroids?

Authors:  Rodrigo Cavallazzi; Sonal Singh
Journal:  Curr Infect Dis Rep       Date:  2011-06       Impact factor: 3.725

Review 4.  Inhaled corticosteroids for stable chronic obstructive pulmonary disease.

Authors:  Ian A Yang; Melissa S Clarke; Esther H A Sim; Kwun M Fong
Journal:  Cochrane Database Syst Rev       Date:  2012-07-11

Review 5.  Effects of inhaled corticosteroids on sputum cell counts in stable chronic obstructive pulmonary disease: a systematic review and a meta-analysis.

Authors:  Wen Qi Gan; S F Paul Man; Don D Sin
Journal:  BMC Pulm Med       Date:  2005-02-11       Impact factor: 3.317

6.  Increased risk of community-acquired pneumonia in COPD patients with comorbid cardiovascular disease.

Authors:  Sheng-Hao Lin; Diahn-Warng Perng; Ching-Pei Chen; Woei-Horng Chai; Chin-Shui Yeh; Chew-Teng Kor; Shih-Lung Cheng; Jeremy Jw Chen; Ching-Hsiung Lin
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-12-05

Review 7.  Budesonide-formoterol (inhalation powder) in the treatment of COPD.

Authors:  Erkan Ceylan
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006

Review 8.  Eosinophilic airway inflammation in COPD.

Authors:  Shironjit Saha; Christopher E Brightling
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006

9.  Glycyrrhizin and related compounds down-regulate production of inflammatory chemokines IL-8 and eotaxin 1 in a human lung fibroblast cell line.

Authors:  Sachiko Matsui; Hiroatsu Matsumoto; Yoshiko Sonoda; Kumi Ando; Eriko Aizu-Yokota; Toshitsugu Sato; Tadashi Kasahara
Journal:  Int Immunopharmacol       Date:  2004-12-15       Impact factor: 4.932

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.